Evidence map›Paper›PMID 37628816›Full record

ArticleInternational journal of molecular sciences2023

Endogenous Galectin-1 Modulates Cell Biological Properties of Immortalized Retinal Pigment Epithelial Cells In Vitro.

Caspar Liesenhoff, Simon Martin Paulus, Caroline Havertz, Arie Geerlof, Siegfried Priglinger, Claudia Sybille Priglinger, Andreas Ohlmann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Glycosylation of the retina.Biochemical Society transactions · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Caspar LiesenhoffDepartment of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany.
Simon Martin PaulusDepartment of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany.
Caroline HavertzDepartment of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany.
Arie GeerlofProtein Expression and Purification Facility, Institute of Structural Biology, Helmholtz Center Munich for Environmental Health, 85764 Neuherberg, Germany.ORCID 0000-0001-7295-9948
Siegfried PriglingerDepartment of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany.ORCID 0000-0002-5580-612X
Claudia Sybille PriglingerDepartment of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany.
Andreas OhlmannDepartment of Ophthalmology, University Hospital, LMU Munich, Mathildenstrasse 8, 80336 Munich, Germany.
LMU Klinikum · DE

Funding

Deutsche Forschungsgemeinschaft OH 214/4-3; PR 1248/2-3
6 · The paper itself

Abstract

In the eye, an increase in galectin-1 is associated with various chorioretinal diseases, in which retinal pigment epithelium (RPE) cells play a crucial role in disease development and progression. Since little is known about the function of endogenous galectin-1 in these cells, we developed a galectin-1-deficient immortalized RPE cell line (ARPE-19-LGALS1

Indexed as

Galectin 1RNA, Guide, CRISPR-Cas SystemsActinsEpithelial CellsHumansRetinal PigmentsActinsGalectin 1Retinal PigmentsRNA, Guide, CRISPR-Cas SystemsARPE-19cell attachmentcell proliferationcell viabilitycompensatory gene expressionepithelial–mesenchymal transitiongalectin-1galectin-1 deficiencygalectin-1 knockoutretinal pigment epithelium cells

Identifiers

PMID37628816
PMCPMC10454680
OpenAlexW4385740804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.